Testosterone intranasal (low-dose) - Acerus Pharmaceuticals

Drug Profile

Testosterone intranasal (low-dose) - Acerus Pharmaceuticals

Alternative Names: MPP-14; Noseafix; TBS-2; Tefina

Latest Information Update: 10 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mattern Pharmaceuticals
  • Developer Acerus Pharmaceuticals; Trimel Biopharma
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anorgasmia
  • No development reported Decreased libido

Most Recent Events

  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
  • 30 Jun 2015 Testosterone intranasal (low-dose) is still in phase II trials for Anorgasmia in USA, Australia and Canada
  • 23 Jan 2015 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top